Stocks finished mixed Monday with the Nasdaq posting another record close on the last trading day of August.
Here are some of the market's biggest gainers for Monday:
1. Aimmune Therapeutics | Percentage Increase Over 171%
Aimmune Therapeutics (AIMT) - Get Aimmune Therapeutics Inc Report shares nearly tripled Monday after Nestle agreed to acquire the maker of peanut allergy treatments in a $2.6 billion deal. Switzerland's Nestle will pay $34.50 a share for Aimmune, which makes Palforzia, the first treatment for peanut allergy to be cleared by the Food and Drug Administration.
2. Akcea Therapeutics | Percentage Increase Over 60%
Akcea Therapeutics (AKCA) - Get Akcea Therapeutics, Inc. Report climbed after its majority owner, Ionis Pharmaceuticals (IONS) - Get Ionis Pharmaceuticals, Inc. Report, said it had agreed to acquire the 24% stake in Akcea it does not already own for $18.15 a share. The total transaction value is about $500 million and is expected to close in the fourth quarter.
3. GameStop | Percentage Increase Over 23%
GameStop (GME) - Get GameStop Corp. Class A Report advanced after RC Ventures disclosed that it has taken a 9% stake in the videogame retailer, making it the third-biggest investor in GameStop behind BlackRock and Fidelity, according to data tracked by Bloomberg.
4. Genworth Financial | Percentage Increase Over 27%
Genworth Financial (GNW) - Get Genworth Financial, Inc. Class A Report shares rose following reports that China Oceanwide Holdings secured financing to complete its purchase of the insurance company. Monday was the deadline for Oceanwide to provide evidence that it had enough financial resources to complete the deal, according to the Motley Fool.
5. I-Mab | Percentage Increase Over 27%
I-Mab (IMAB) - Get I-Mab Report American depositary receipts climbed after the biopharma released its first half 2020 financial results, saying its cash position was $221 million at the end of June, compared with $175 million at the start of the year and that it expected "significant pipeline updates in the second half of the year.